One skin visit, three procedures, and the modifier that either earns money or triggers an audit
The short answer: most same-day dermatology denials and takebacks are not coding mysteries. They are NCCI procedure-to-procedure edits doing exactly what they are designed to do. A biopsy, a destruction, and a Mohs stage can all be paid on one date of service, but only when modifier 25 or modifier 59 describes a service that is genuinely separate. Append the same modifier to force a bundled line through, and you have not rescued the claim. You have created the finding an auditor is looking for.
Modifier 25
Belongs on the E/M only when the visit did real, separate cognitive work beyond the planned procedure.
Modifier 59 / X{EPSU}
Belongs when the second procedure is a different lesion, site, or session, never to unbundle the same lesion.
Mohs 17311-17315
The surgeon is also the pathologist. A same-day biopsy is separate only when it establishes a diagnosis not yet known.
Same date of service, three integumentary code sets
Per the 2026 CPT code set, these are the exact codes in play when a single lesion gets sampled, when precancers get destroyed, and when a confirmed skin cancer heads to Mohs. Hold this reference up against the edit tables and the bundling logic stops feeling random.
Skin biopsy, by technique
- 11102 tangential, single lesion · +11103 each additional
- 11104 punch, single lesion · +11105 each additional
- 11106 incisional, single lesion · +11107 each additional
Premalignant destruction (AKs)
- 17000 first lesion · +17003 second through 14th, each
- 17004 15 or more lesions, one unit
- Benign 17110/17111 and malignant 17260–17286 sit adjacent
Mohs micrographic surgery
- 17311 first stage, head/neck/hands/feet/genitalia
- 17313 first stage, trunk/arms/legs · +17312 / +17314 add'l stage
- +17315 each additional block, any stage
Follow the claim through every NCCI gate
An established patient arrives for a scheduled Mohs on a biopsy-proven basal cell on the cheek. During the visit the dermatologist also treats scalp actinic keratoses and samples a new suspicious spot on the forearm. Here is where the money is won or lost, one node at a time. Each gate splits into the lane where the modifier earns its place and the lane where it is a red flag.
Is there a separate E/M service at all?
The CPT surgical package already pays for the evaluation inherent to every procedure. Modifier 25 is only for a significant, separately identifiable E/M above that baseline work.
The new forearm lesion and the scalp AKs are each evaluated, documented, and drive their own decisions. That is real cognitive work the Mohs package does not include.
Bill 99213-25Patient came only for the pre-planned Mohs, exam is the routine pre-op check, no new problem. Appending 25 to manufacture an E/M is exactly the pattern OIG audits.
Do not bill the E/MSame-day biopsy of the Mohs lesion
CPT is explicit: the Mohs surgeon acts as surgeon and pathologist, so routine intra-op frozen work is bundled into 17311-17315. A separate biopsy is reportable only when it establishes a diagnosis that was not already known.
Diagnosis was NOT established beforehand. A same-day biopsy plus frozen section confirms cancer, then Mohs proceeds. CPT Mohs guidelines allow the biopsy and pathology separately with modifier 59.
17311, then 11106-59 + 88331-59Diagnosis was already confirmed on a prior date. Re-biopsying the same lesion the morning of Mohs and adding 59 unbundles work the Mohs code already pays for. That is not rescue, it is a fabricated line.
Bill 17311 onlyDestruction and biopsy on different lesions
Biopsy is column-two to destruction when it is the same lesion, because you do not separately bill sampling a lesion you then destroy. Different anatomic lesions are a different story.
Scalp AKs destroyed, forearm lesion biopsied. Different lesions, different sites. Modifier XS (separate structure), the precise subset of 59, correctly reports two distinct services.
17000, +17003, 11102-XSYou biopsy a lesion and then destroy that same lesion in the same session, then append 59 to bill both. The biopsy is bundled into the destruction. Adding 59 to split one lesion into two payments is an unbundling edit failure.
Bill the destruction onlyMUE and the modifier indicator, before you drop the claim
Every pair above still has to clear two more checks. The PTP modifier indicator decides whether a modifier can override the edit at all, and Medically Unlikely Edits cap the units per line regardless of documentation.
Indicator 1 means the edit is conditionally bypassable when a distinct service is documented. Stage add-ons (+17312/+17314) and blocks (+17315) are reported per the operative note, within MUE limits.
Submit with documentation on fileIndicator 0 means no modifier can unbundle the pair, period. Forcing 59 onto an MI-0 edit, or billing stages above the MUE, is a denial at best and a pattern at worst.
Rework the coding, do not modifier-force itThe bundling logic in one table
This is how the NCCI Procedure-to-Procedure edits behave for the pairs in the encounter above. The modifier indicator is the single field that decides whether modifier 25 or 59 is even allowed to work. When the indicator is 0, no amount of documentation opens the gate.
| Column 1 (primary) | Column 2 (bundled) | Mod indicator | When it may separate |
|---|---|---|---|
| 17311 Mohs | 11106 biopsy | 1 | Diagnosis not previously established; same-day biopsy confirms cancer. Append 59 to biopsy and to the frozen path (88331). Per CPT Mohs guidelines. |
| 17311 Mohs | 99213 E/M | 1 | A significant, separately identifiable problem is evaluated. Append 25 to the E/M. Not for the routine pre-op assessment. |
| 17000 destruction | 11102 biopsy | 1 | Biopsy is a different lesion / site than the one destroyed. Use XS. Same lesion stays bundled. |
| Destruction of a lesion | Biopsy of that same lesion | 0 | Never separates. Sampling a lesion you destroy in the same session is included. No modifier overrides indicator 0. |
Always verify the live pair against the current CMS NCCI PTP edit file, since column assignments and indicators are refreshed each quarter. The pattern above is stable; the specific effective values are not.
Where the dollars actually disappear
Under-coding and over-coding lose money the same day
Dropping the E/M entirely because a coder is scared of modifier 25. The separate scalp and forearm work was real and payable. Fear-driven downcoding is silent lost revenue.
Blanket modifier 59 on every second procedure. It clears the edit today and builds the utilization outlier profile that draws the audit tomorrow.
Same-day biopsy of an already-confirmed Mohs lesion. It reads like extra revenue and codes as a duplicate the Mohs family already pays for.
Ignoring the modifier indicator. Appending 59 to an indicator-0 pair guarantees a denial, plus a rework cost that erases the margin on the line.
The guidelines this page is built on
2026 CPT Code Set (AMA)
Mohs 17311-17315, skin biopsy 11102-11107, premalignant destruction 17000-17004, and the surgical package guidelines that define modifiers 25 and 59.
NCCI Policy Manual for Medicare Services, 2026
Chapter 3, Integumentary System (CMS). Governs biopsy-into-destruction and biopsy-into-Mohs bundling and the same-lesion rule.
NCCI Procedure-to-Procedure (PTP) Edits, Q1 2026
CMS quarterly edit files with column-one / column-two pairs and the 0 / 1 modifier indicator that decides whether a modifier is allowed.
Medically Unlikely Edits (MUE), CMS 2026
Per-line unit ceilings for stages and blocks, applied regardless of documentation.
CMS "-X{EPSU}" Subset Modifiers
XE, XS, XP, XU as the specific alternatives to modifier 59; XS is separate structure. Never defaults, always documentation-driven.
CMS Physician Fee Schedule Final Rule, CY 2026
The payment context these edits are enforced within for dermatology procedures.
AAD Mohs Appropriate Use Criteria
American Academy of Dermatology criteria supporting when Mohs is the indicated modality for a given tumor and site.
HHS-OIG Work Plan
Ongoing scrutiny of modifier 25 and dermatology E/M billed with same-day procedures, the reason the red-flag lane matters.
Stop guessing at modifier 25 and 59 on your dermatology claims
ASP-RCM Solutions builds the NCCI logic above directly into how we code and scrub dermatology claims, so the E/M gets paid when it should, Mohs same-day biopsies are separated only when the diagnosis was genuinely open, and no line rides on a modifier it cannot support. Fewer denials, cleaner audit posture, more of the revenue you already earned.
Get a dermatology coding and NCCI review →Operator to operator, on your real claims. No fabricated benchmarks, no boilerplate.
Related reading
The procedure never decides the claim. The diagnosis and the benefit that covers it do.
Medical dental cross coding CDT 2026 made simple. A side-by-side matrix showing when the same procedure belong
Read →InsightHow Colorado got here
Colorado's FY2026-27 budget sets the adult dental cap at $3,000 while cutting every Medicaid rate 2% effective
Read →Field noteThe claim is not dental. It is medical, and coded wrong.
A side-by-side field guide that pairs medically necessary dental services with their CPT equivalents, so traum
Read →